Zura Bio Limited (ZURA)
ZURA trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026.
Profile
| Field | Value |
|---|---|
| Ticker | ZURA on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Country | Cayman Islands |
| IPO year | Not reported by the screener |
| SEC CIK | 0001855644 |
| SEC industry code | Biological Products, (No Diagnostic Substances) |
| Incorporated in | Cayman Islands |
Financials
Foreign filer: no machine-readable annual figure in SEC data.
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-10-27 |
| Cash and burn | $187.7M cash; operating cash flow -$16.2M a quarter. | Report 2026-09-30 |
| Shares outstanding | 96,325,411 (2026-10-27); 65,023,308 a year earlier; 43,593,678 three years earlier. | Cover page 2026-10-27 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 1 S-3/F-3 shelf filings; 2 424B5 takedowns, 2 at the market | Latest 2026-02-25 |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | WithumSmith+Brown, PC, East Brunswick, New Jersey, United States | PCAOB Form AP 2026-03-20 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $12.5M, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | Not filed | -$25.8M | -$19K | $187.7M | No debt tags | Needs four quarters | 10-Q 2026-10-27 |
| Q2 2026 2026-06-30 | Not filed | -$26.3M | $18.9M | $205.1M | No debt tags | Needs four quarters | 10-Q 2026-08-11 |
| Q1 2026 2026-03-31 | Not filed | -$24.2M | -$18.9M | $225.6M | No debt tags | Needs four quarters | 10-Q 2026-05-07 |
| Q4 2025 2025-12-31 | Not filed | -$17.2M | -$64.8M | $109.4M | No debt tags | Needs four quarters | 10-K 2026-03-19 |
| Q3 2025 2025-09-30 | Not filed | -$18.0M | -$15K | $139.0M | No debt tags | Needs four quarters | 10-Q 2026-10-27 |
| Q2 2025 2025-06-30 | Not filed | -$16.0M | $11.0M | $154.5M | No debt tags | Needs four quarters | 10-Q 2026-08-11 |
| Q1 2025 2025-03-31 | Not filed | -$17.4M | -$11.1M | $170.6M | No debt tags | Needs four quarters | 10-Q 2026-05-07 |
| Q4 2024 2024-12-31 | Not filed | -$13.6M | -$10.8M | $176.5M | No debt tags | Needs four quarters | 10-K 2026-03-19 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document FORM S-3 | S-3 | 2026-10-27 |
| Latest annual report | 10-K | 2026-03-19 |
| Latest quarterly / interim | 10-Q | 2026-10-27 |
| Latest current report FORM 8-K | 8-K | 2026-11-09 |
| Latest proxy | DEFA14A | 2026-05-22 |
Source: SEC EDGAR submissions feed, 447 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -69.7% |
| 1 month | -70.7% |
| 3 months | -78.0% |
| Year to date | -76.3% |
| 1 year | -70.3% |
| From 52-week high | -82.4% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Biological Products (No Diagnostic Substances)
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| VYGR | Voyager Therapeutics Inc. | $1.63 | -5.78% | $101.4M |
| MOLN | Molecular Partners AG | $2.70 | -8.21% | $101.2M |
| ARMP | Armata Pharmaceuticals Inc. | $2.99 | -22.74% | $111.2M |
| OTLK | Outlook Therapeutics Inc. | $0.3960 | -4.12% | $96.4M |
| CMPX | Compass Therapeutics Inc. | $0.6615 | -14.51% | $119.1M |
| LENZ | LENZ Therapeutics Inc. | $3.82 | -7.51% | $120.0M |
| BDTX | Black Diamond Therapeutics Inc. | $1.53 | +4.08% | $87.9M |
| CRDL | Cardiol Therapeutics Inc. Class A Common Shares | $0.9798 | -2.02% | $125.1M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier